• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A method for the purification of human fibroblast interferon by the successive treatments of a crude interferon solution with a strongly acidic ion exchanger and a chelating carrier which contains a chelating residue chelated with at least one metal ion selected from the group consisting of Co", Ni++, Zn", and Cu++.
    公开号:SU1389667A3
    申请号:SU792838809
    申请日:1979-11-06
    公开日:1988-04-15
    发明作者:Хосои Казуо；Озава Хитоси
    申请人:Торэй Индастриз Инкорпорейтед (Фирма)；
    IPC主号:
    专利说明:

    SLE
    c; o
    O5 O5

     cm
    The invention relates to medicine and relates to a method for the purification of human fibroblast interferon.
    The aim of the invention is to increase the degree of purification of human fibroblast interferon, which is achieved by chromatography on cross-linked dextran containing sulfonyl groups and on agarose derivatives, including the carboxymethylamino group and ion, or Ni, or, or Cu.
    The method is carried out as follows.
    A solution of human fibroblastic interferon with a pH of 1-3 is passed through a column with SP-Sephadex, the flask is washed with water, the elution of interferon is carried out at pH 7.0-11.0 and then As a metal ion, Ca, or Ni, or Zn, or, interferon elution is carried out with a solution of histone.
    Example 1. Interferon-containing liquid was prepared by treating human fibroblastic cells (diploid culture usual) with Poly-I: Poly-C in Eagle-Meme medium followed by treatment with cycloheximide and actinomycin D (superinduction).
    An interferon solution (pH 7.4), having an interferon activity of 3200 IU / s and a protein concentration of 20 µg / ml, is adjusted to pH 2.0 with hydrochloric acid and passed through a column with transversely crosslinked dextran containing a sulfonyl group, SP - Sephadex (200 ml, 4.6 cm x 12 cm). After passing 60 liters of the solution containing interferon (with a total activity of 1.9 X), the column is washed with 2 liters of water. The eluate contained 9.5 X nE (5%) of interferon activity. The column was then washed with 0.1 M Na-phosphate buffer at pH 8.3, with interferon coming out in the first 2.28 L of eluent. This fraction contained 1.8 X 10® N (94%) of interferon activity and 23 mg of protein. The specific activity was 8 x 10 IU / mg. squirrel. The concentration was 26 times and the purification rate 50 times.
    The metal chelate chromatography carrier is prepared by
    0
    five
    0
    five
    0
    five
    0
    five
    0
    five
    Porat method. Imidacetic acid (14g) and sodium carbonate (20g) are dissolved in water (100 ml) and exposed to epoxy-activated Sepharose - 6B (135 ml, wet volume) for 16 hours at 56 ° C. After filtration and washing, the carrier is treated with 1 M ethanol-amine (100 ml) for 4 hours at 56 ° C, filtered, washed and stored at 4 ° C.
    A column for Zn - chelate chromatography (45 ml, 3 cm X 6.4 cm) is prepared by passing a 1% zinc chloride solution through a column carrier. 2.28 l of eluent is passed through this column from the SP-Sephadex column and 800 ml of physiological saline. The solution that passed through the column and the washing solution contained 8 x 10 IU (4%) of interferon activity. The column is then washed with a 0.1 M solution; Na-phosphate buffer (pH 4.5) containing saline (1: 9, volume per volume). The first fraction (262 ml) contained 1.4 x (72%) of interferon activity. The concentration of interferon in this fraction of 1DII was 5.3 X 10 W / pc and the protein concentration was 2 µg / ml with a specific activity of 2.7 x 10 IU / mg protein, which indicates purification 1700 times and concentration 166 times compared with the original solution.
    The original solution of interferon containing pyrogenic substances, gave a positive reaction when tested by Limuly test. A part of the pyrogenic substances after passing through SP-Sephadex without reducing the activity of interferon again gave a positive reaction when tested according to the Limulus test. The remaining pyrogenic substances did not linger on the chelate column and were removed during passage through the column and washing. The eluent from the metal chelate column contained insignificant amounts of pyrogenic substances.
    A portion of the final eluent fraction after filtration through a 0.2 micron filter was administered intravenously to three rabbits (1.5. X 10 IU / kg body weight). The amount of temperature increase was 0 ° C.
    Example2. As the initial solution of interferon use
    interferon like in example 1. An acidified solution of interferon (48 l containing 5000 IU / mp, total activity 2.4 x 10 IU) with a protein content of 25 µg / ml is passed through a column with 200 ml of SP-Sephadex and the column is washed 2 l water. Interfero elute with 2.0 L of phosphate buffer pH 8.3. Got 2 X 10 IiE (83%) of activity and 100 ug (10.4%) of protein (concentration 20 times and purification 10 times). A portion of the eluent from the SP-Sephadex column (200 ml with an activity of 2 X 10, total protein content 10 mg) was passed at a rate of 8 ml / h through a column with 2 ml of chelate carrier. After washing with 20 MP of water and 20 ml of a physiological solution, the interferon is diluted with a 0.2 M histidine solution containing 0.2 M sodium chloride pH 7.5. Eluent 6.0 ml) contained 2.3 x 10 11E / m interferon (total activity, X 10 no. / 69%) and 15 µg / ml protein (total protein 0.09 mg, yield 0.9%. Specific the activity of this fraction was 1.5 x 10 HE / mg protein, the concentration was 460 times, purification 750 times as compared with the initial solution of interferon.
    PR and ME 3. The method is carried out according to Example 2 with the exception that a Ni-xelate column is used instead of a Co-chelate column.
    Eluent (6.0 ml) contained 2.3 ml of X IO fIE / ml (yield 69%) and 50 μg / ml protein (yield 3%). The specific activity was 5 x 10 IiE / ml protein.
    Example D. The method is carried out according to Example 2 with the exception that the Zn-chelate column is used instead of the Co-chelate column.
    Eluent (6.0 ml) contained 2.3 x X 1 o ME / MP (yield 69%) and 30 μg / ml protein (yield 1.8%). The specific activity is 8 X 10 IU / mg protein.
    Example 5. The method is carried out according to Example 2 with the exception that the Cu-chelate column is used instead of the Co-chelate column.
    Eluent (6.0 ml) contained 1.8 x 10 10 G-TE / ml (yield 54%) and 150 μg / ml protein (yield 9%). The specific activity of 1.2 X IU / mg.
    0
    five
    0
    five
    0
    five
    0
    five
    0
    five
    Example 6. The elution of interferon from the column with SP-Sephadex was carried out at pH 11.0.
    The original interferon B Eagle-Meme medium with a total activity of 3.2 X, total protein of 89 mg, specific activity of 3.6 x 10 IU / mg was adjusted to pH 2.0 by adding 6 N HCl, then mixed with 3.0 g of SP -sefadex G-25 (Pharmacia) and stirred overnight at. After settling for 3 hours, the supernatant was removed and SP-Sephadex-Mbffiaitft 3 times 50 ml of distilled water. A suspension of SP-Sephadex (volume in the swollen state of about 20 MP) in 40 MP of distilled water is divided between 20 plastic tubes. 10 MP of 0.1 M sodium phosphate (monobasic, dibasic or tribasic) are added to each of these tubes, pH adjustment, respectively, to 3,4,5,6,7,8,9, 10,11,12.
    Tubes containing SP-Sephadex and phosphate buffer for mixing were thoroughly shaken for 1 hour. And the supernatant from each tube was passed through a 0.2 mmk filter. After that, the activity of interferon in 10 / filtrates is determined (see Table 1).
    Interferon is eluted at pH 7.0-11.0.
    Example 7. Interferon in O, 1 M sodium phosphate solution (pH 7.6). 16 ml with a total activity of 8 x 10 ME, total protein of 8 mg, specific activity of 10 X 10 IU / mg of protein, eluted from SP-Sephadex, is passed through a column with Zn-chelate agarose in an amount of 2 MP and the column is washed O, 1 M sodium phosphate solution and distilled water. Thereafter, Zn chelate agarose is divided into 4 portions and placed in 4 plastic tubes. To each tube was added 5 ml of a buffered 0.2 M solution of sodium acetate containing sodium chloride at a concentration of 1 M and having a pH of 1.5, respectively; 3.0; 4.5; 6.0, mix thoroughly for several minutes and determine the activity of interferon in each tube (see Table 2).
    Interferon is eluted at pH 3.0-5.5.
    513896676
    According to a known method, the volume of the preliminarily carried out chromate-chelate carrier is applied to the graph on a crosslinked dextra-cleaning 14 volumes of interferon, and not containing a sulfonyl group
    in the proposed method, 1 volume of no - at an elution pH of 7.0-11.0, and chelated
    the cleaner is used for purifying chromatography from about 1000-6000 volumes of interferon. using derivative agarose,
    containing a biscarboxymethylamino formula of the invention, a group, and as a metal ion
    10 ion Co, or Ni, or Zn
    The method of purification of human fibsi, and edudi is carried out on interstitial macrobial, by histidine in the case of Co, tall chelate chromatography, or Ni, Zn, or an acidic a product with a pH of 3.0 - 5.5 in the case of an increase in the productivity of the process- 5 Zn-chelate chromatography.
    Table 1
    10 ion Co, or Ni, or Zn
    or
    table 2
    权利要求:
    Claims (1)
    [1]
    Claim
    The method of purification of human fibroblast interferon by metal chelate chromatography, characterized in that, in order to increase the productivity of the process, preliminary chromatography is performed on cross-linked dextran containing a sulfonyl group at an elution pH of 7.0-11.0, and a chelating one chromatography is carried out using an agarose derivative containing biscarboxymethyl Lamino group, and Co + *, or Ni ++ , or Zn 4 * or Cii + * as a metal ion, and elution is carried out with a histidine solution in the case of Co ++ , Ni + *, Zn ++ , or C ++ or acidic solution with a pH of 3.0 - 5.5 in the case of Zn ++ chelate chromatography.
    Table!
    pH InterferonME....................._ Exit,% Specific activity, IU / mg protein 3 9 x 10 S<0.6 Not determined 4 9 x 10 3<0.6 Not determined 5 1.0 x 10 40.6 0.5 x 10 5 6 2.7 x 10 * 0.6 0.6 x 10 5 7 4.2 x 10 526 .6.8 x 10 * 8 7.5 x 10 547 11.0 x 10 5 9 6.6 x 10 541 9.9 x 10 5 10 5.6 x h 10 535 7.4x10 s eleven 2.5 x 10 516 2.5 x 10® 12 1.4 x 10 s 9 1.3 x s 5 Table and 2 pH activity of inter- Output Asset - Specific Asset - feron, ME x 10 ^ 7o nost IU / mg protein x 10 1.5 * 0.2 10 '0.2 s oh 1,2 60 0.7 4,5 2.0 100 1,0 5.5 1.4 70 0.6 6.0 0.2 10  0.1
    k To adjust pH Use hydrochloric acid.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1389667A3|1988-04-15|Method of purifying fibrinous interferon of human being
    US4275056A|1981-06-23|HGI-Glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same
    US4397840A|1983-08-09|Novel erythropoietin product and method for the preparation thereof
    US4359389A|1982-11-16|Method for the purification of interferon
    EP0471701B1|1994-10-19|Novel tnf-inhibit proteins and their preparation
    DE2600971C2|1985-12-12|Process for the preparation of bovine insulin complexes with sustained action and medicaments containing these complexes
    EP0118808B1|1990-11-22|Purification of interferon
    US4172071A|1979-10-23|Chromophore blue adsorbent method for the purification of preparations having an interferon type activity
    EP0447585A1|1991-09-25|Process for manufacturing an intravenously tolerant immunoglobulin-G preparation
    US3868357A|1975-02-25|Alkanedioic acid derivatives of insulin
    JP2511159B2|1996-06-26|Pharmaceutical formulations for the treatment of immune deficiency conditions
    US4541952A|1985-09-17|Purification method of human interferon
    JP3438735B2|2003-08-18|Method for isolating human albumin from supernatant IV, especially IV-4 or corn fraction V or a similar supernatant or fraction
    US4597899A|1986-07-01|Process for obtaining a factor XIII preparation, and its use
    US4256631A|1981-03-17|Process for the preparation of immunoglobulin for intravenous administration
    EP0190606B1|1990-05-09|Sorbent for the purification of proteins
    LU82673A1|1982-02-17|HOMOGENES FIBROBLASTEN-INTERFERON UND DESSEN HERSTELLUNG
    US3864325A|1975-02-04|-| insulin derivatives
    JP2001504092A|2001-03-27|Method for producing an IgM formulation for intravenous application
    EP0301374B1|1993-02-03|Process for the purification of the placenta tissue protein pp4
    CA1105383A|1981-07-21|Immunoglobulin having a reduced complement fixation, a process for its preparation and agents containing this immunoglobulin
    Lau et al.1983|Purification of a pituitary polypeptide that stimulates the replication of adipocyte precursors in culture
    US5164377A|1992-11-17|Sulphated glycosaminoglycuronan with antithrombotic activity
    DE1189674B|1965-03-25|Method for the isolation of alpha-antitrypsin
    EP0425821A1|1991-05-08|The use of human ADF | for producing a medicament
    同族专利:
    公开号 | 公开日
    EP0011435A1|1980-05-28|
    DE2962359D1|1982-04-29|
    JPS5728270B2|1982-06-15|
    EP0011435B1|1982-03-24|
    US4257938A|1981-03-24|
    JPS5564799A|1980-05-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3144390A|1960-06-28|1964-08-11|Nat Res Dev|Process for the purification of interferon|
    GB980227A|1962-08-16|1965-01-13|Glaxo Lab Ltd|Purification and/or concentration of material containing interferon|
    GB1055895A|1963-12-10|1967-01-18|Glaxo Lab Ltd|Interferon purification|
    US3975344A|1974-10-02|1976-08-17|G. D. Searle & Co.|Interferon purification|
    NL7605805A|1976-05-28|1977-11-30|Stichting Rega V Z W|METHOD OF CLEANING INTERFERON.|NO811118L|1980-04-03|1981-10-05|Biogen Nv|DNA SEQUENCES, RECOMBINANT DNA MOLECULES, AND PROCEDURE FOR PREPARING POLYPEPTIDES|
    JPS5936963B2|1981-03-10|1984-09-06|Asahi Chemical Ind|
    CA1204681A|1981-04-20|1986-05-20|Cetus Corporation|Method and vector organism for controlledaccumulation of cloned heterologous gene products inbacillus subtilis ii|
    JPH0112760B2|1982-05-17|1989-03-02|Toray Industries|
    US4485038A|1982-10-19|1984-11-27|Health Research |Method for the production and purification of human leukocyte interferon|
    US4485017A|1982-12-22|1984-11-27|Cetus Corporation|Isolation of human interferon by immunosorbent and high performance liquid chromatography|
    CA1231306A|1983-03-03|1988-01-12|Erich Hochuli|Purification of interferon|
    US4723000A|1983-07-05|1988-02-02|Biospectrum, Inc.|Human interferon gamma and interleukin-2|
    WO1985000758A1|1983-08-17|1985-02-28|Litovitz, Theodore, Aaron|Improved silica-based chromatographic supports containing additives|
    US4648975A|1983-08-17|1987-03-10|Pedro B. Macedo|Process of using improved silica-based chromatographic supports containing additives|
    US4658017A|1984-02-14|1987-04-14|Health Research, Inc. |Method for the large scale purification of human fibroblast interferon|
    US4732683A|1986-12-02|1988-03-22|Biospectrum, Inc.|Purification method for alpha interferon|
    US6251278B1|1987-06-08|2001-06-26|Chromatochem, Inc.|Process for separating a substance from a mixture|
    JP2749094B2|1989-01-13|1998-05-13|日本原子力研究所|Method for producing multifunctional filtration membrane having iminodiacetic acid group|
    EP0551535A1|1992-01-13|1993-07-21|SCLAVO S.p.A.|Process for the purification of recombinant human beta interferon, beta interferon thus purified, and pharmaceutical compositions which contain them|
    WO1997007820A1|1995-08-30|1997-03-06|Toray Industries, Inc.|Remedy for heart diseases|
    WO2002074806A2|2001-02-27|2002-09-26|Maxygen Aps|New interferon beta-like molecules|
    JP4424988B2|2001-09-25|2010-03-03|国立がんセンター総長|Search for cancer markers by a novel screening method|
    US8137548B2|2003-10-17|2012-03-20|Zirchrom Separations, Inc.|Chelator-modified inorganic oxide particles|
    KR100524871B1|2003-12-04|2005-10-31|씨제이 주식회사|Processes for the purification of interferon beta|
    KR100524872B1|2003-12-04|2005-11-01|씨제이 주식회사|Processes for the purification of interferon beta|
    US20070015689A1|2005-06-23|2007-01-18|Alza Corporation|Complexation of metal ions with polypeptides|
    DE102009032179A1|2009-07-07|2011-01-13|Biogenerix Ag|Process for purifying interferon beta|
    CA2931547A1|2013-12-09|2015-06-18|Durect Corporation|Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP13703578A|JPS5728270B2|1978-11-07|1978-11-07|LV930213A| LV5138A3|1978-11-07|1993-03-31|Method of detecting human fibroblast interferon|
    LTRP1136A| LT2593B|1978-11-07|1993-09-27|THE FOUNDATION OF HUMAN FIBROBLAST INTERFERENCE|
    [返回顶部]